Author: OurCrowd

[SaNOtize in Business Wire] UK Clinical Trial Confirms SaNOtize’s Breakthrough Treatment for COVID-19

Mar 15, 2021 |

VANCOUVER, British Columbia & SURREY, England–(BUSINESS WIRE)–Biotech company SaNOtize Research & Development Corp., (SaNOtize), Ashford and St Peter’s Hospitals NHS Foundation Trust in Surrey, UK, and Berkshire and Surrey Pathology Services, UK, today announced results of clinical trials indicating that SaNOtize’s Nitric Oxide Nasal Spray (NONS) represents a safe and effective antiviral treatment that could prevent the transmission of COVID-19, shorten its course, and reduce the severity of symptoms and damage in those already infected. Register...

Read More

[BrainQ in Mashable] Israeli firm’s smart headgear reduces disability via artificial brainwaves

Mar 15, 2021 |

AI has opened doors for use of smart tech to assist people in day to day life, be it increased convenience in personal life or ease of access to public services. Stimulating the human brain via medtech has also proved to be successful in helping people with neurological ailments, and the technique has even helped Emirati authorities decode a criminal’s mind. Read more...

Read More

[TytoCare in Healthcare] Spectrum Health partners with TytoCare to expand remote care

Mar 15, 2021 |

Spectrum Health, one of the top-rated health systems in the US, is partnering with telehealth company TytoCare to expand its virtual care and remote patient monitoring offerings. Based in Michigan, Spectrum is expanding its telehealth offerings by integrating TytoCare into its services, giving clinicians the ability to diagnose and treat patients remotely with TytoCare’s handheld AI-powered examination kit. Read...

Read More

[SaNOtize in Crowdfund Insider] OurCrowd Portfolio Company SaNOtize’s COVID Treatment Reduces Viral Load by 95% in 24 Hours

Mar 15, 2021 |

OurCrowd portfolio company SaNOtize says that a UK clinical trial has delivered solid results as COVID-19 treatment. A self-administered nasal spray is said to reduce the viral load by more than 95% in 24 hours and by 99% in 72 hours. Trial results indicated that treatment accelerated clearance of SARS-CoV-2 by a factor of 16-fold versus a placebo. Read...

Read More